Facio Therapies announced today that it has raised €4.8 million from a group of shareholders, which includes families affected by FSHD, the French charity Amis FSH and drug discovery partner, Evotec.
Facio and Evotec have been screening hundreds of drugs for their ability to block the production of DUX4 protein in muscle cells with FSHD. The €4.8mil funding will help to accelerate this screening and the identification of pre-clinical candidates.
Get the latest FSHD research news
Find out about MDUK-funded FSHD research